Khachanova N V, Bakhtiyarova K Z, Boyko A N, Vlasov Y V, Davydovskaya M V, Evdoshenko E P, Zakharova M N, Kotov S V, Popova E V, Sivertseva S A, Totolyan N A, Khabirov F A
Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.
Medical University of Bashkiriya, Ufa, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(3):82-91. doi: 10.17116/jnevro202012003182.
Alemtuzumab (Lemtrada) is a recombinant humanized IgG1 kappa monoclonal antibody to the surface cell glycoprotein, a CD52 differentiation cluster. The drug is approved for use in more than 65 countries, including the Russian Federation. The drug is one of the most effective methods of treating patients with aggressive multiple sclerosis, but the risk management plan should be followed. The safety profile of the drug includes infusion-associated reactions, thyroid dysfunction, immune cytopenia, acute cardiovascular events, infections, and other autoimmune diseases. This publication provides updated practical recommendations for the use of the drug and ensuring the safety of patients treated with alemtuzumab.
阿仑单抗（Lemtrada）是一种重组人源化IgG1κ单克隆抗体，作用于表面细胞糖蛋白，即CD52分化簇。该药物已在包括俄罗斯联邦在内的65多个国家获批使用。它是治疗侵袭性多发性硬化症患者最有效的方法之一，但应遵循风险管理计划。该药物的安全性包括输液相关反应、甲状腺功能障碍、免疫性血细胞减少、急性心血管事件、感染及其他自身免疫性疾病。本出版物提供了关于该药物使用及确保接受阿仑单抗治疗患者安全的最新实用建议。
